{{insights.date}}
{{insights.type}}
{{insights.contentTypeTag}}
Todd A. Lorenz
Partner
Todd Lorenz has been representing serial entrepreneurs, startups, research institutions, investors, and public and private companies throughout the US, Canada, Europe and Asia on all aspects of domestic and international patent procurement, defense and enforcement for more than 30 years, including Nobel laureates in cancer immunotherapy and nucleic acid therapeutics. Todd’s practice encompasses strategic patent prosecution and counseling, transactional due diligence, opinion work, licensing and litigation in a broad range of technical disciplines, including immunology, oncology, dermatology, neurobiology, transplantation, drug delivery, digital health, diagnostics, industrial biotechnology and laboratory instrumentation. He is known for working closely and attentively with his clients throughout their ensuing product life cycles to create comprehensive, layered and effective patent portfolios.
Todd’s personal patent drafting and prosecution experience includes proteins, peptides, antibodies and antibody engineering, ADCs, cellular immunotherapies (e.g., CAR-T, NK, CAR-NK, TaNK), stem cells and stem cell therapies, gene therapies (both DNA and RNA), expression systems, genetic engineering (including CRISPR), transgenic animals, small molecules (e.g., toxins, biguanides, cannabinoids), delivery platforms (e.g., polymers, liposomes, chitosan, enteric coatings), synthetic tissues, 3D bioprinting, medical devices, laboratory hardware, protein purification, separation and lyophilization, and digital therapeutics.
In particular, Todd has contributed to the patent protection for Thymoglobulin®, YERVOY® (ipilimumab), TYSABRI® (natalizumab), OZURDEX®, and AspyreRx™, among other approved drug products, as well as numerous current clinical candidates including EG-70 (detalimogene voraplasmid), ADI-001 (allogeneic γδ CAR T cells), INM-755 (cannabinol), ANJ900 (metformin DR), and ABD-147 (radiopharmaceutical biologic). He also developed, implemented and defended the worldwide patent portfolios for the JOINTstat® diagnostic test and the OmniRat®, OmniMouse® and OmniFlic™ suite of transgenic animals, and in early formative training was fundamentally involved in extensive worldwide litigation relating to Taq DNA polymerase and the polymerase chain reaction.
With an academic background in biology and biomedical engineering at Rensselaer Polytechnic Institute, clinical research experience in cancer immunotherapy at Harvard Medical School, and practical hands-on experience in drug development, formulation and commercialization with a transdermal startup that he co-founded in 2008, Todd brings a wide range of capabilities throughout the biotechnology and pharmaceutical arts to his law practice.
- Patented CTLA-4 Blockade on behalf of 2018 Nobel laureate James P. Allison and his colleagues at U.C. Berkeley, leading to the development of the first immune checkpoint inhibitor for oncology.
- Patented a series of fully human monoclonal antibody production platforms (OmniRat®, OmniFlic®, OmniMouse® and UniRat®) for a serial entrepreneur in the recombinant animal engineering space; now out-licensed to more than 35 companies worldwide.
- Managing and expanding the worldwide patent portfolio for a US$2 billion/year antibody therapeutic for treating multiple sclerosis and Crohn’s disease for a major biotech client.
- Developing and implementing the worldwide patent portfolio for an emerging cell therapy company focused on allogeneic CAR-T cells.
- Developing and implementing the foundational patent portfolio for a cutting-edge startup biotech company creating synthetic tissue structures for human transplantation by way of 3D-bioprinting.
- Advising a revolutionary digital therapeutics company on IP strategy to protect their clinically successful behavioral modification technology platform for treating metabolic disorders.
- Advising a nascent RNAi therapeutics company on the in-licensing, implementation and expansion of their foundational university IP portfolio in the CNS space.
Education
- Boston University School of Law, J.D., cum laude, 1993
- Rensselaer Polytechnic Institute, B.S., 1988
Admissions
- California, 1995
- U.S. Patent and Trademark Office
Courts
- U.S. Ct. of App., Federal Circuit
- U.S. Ct. of App., Ninth Circuit
- Speaker, “Translation of Bioprinted Tissues into the Clinic,” Printing the Future of Therapeutics in 3D, Peter Wall Institute for Advanced Studies, Vancouver, BC, Canada, May 6-8, 2019.